Figure 5From: RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapiesSerum markers and mediators of inflammation in adjuvant-induced arthritis (AIA) rats. Values were determined on day 14 post onset, 10 days after the initiation of treatment. Data represent means ± standard error of the means, n = 8/group. cSignificantly different from control (nonarthritic) rats, P < 0.05. vSignificantly different from vehicle (Veh)-treated arthritic rats, P < 0.05. oSignificantly different from osteoprotegerin (OPG)-treated arthritic rats, P < 0.05. α1AGP, acute-phase protein alpha-1-acid glycoprotein; AIA, adjuvant-induced arthritis; CCL2, chemokine (C-C motif) ligand 2; CRP, C-reactive protein; PGE2, prostaglandin E2.Back to article page